Royalty Pharma, the world’s largest buyer of biopharmaceutical royalties, has launched its first Asia-Pacific office in Hong Kong, tapping into the rapidly expanding cross-border deal flow from mainland China’s biotech industry. As traditional fundraising channels face disruption, royalty financing emerges as a critical alternative for Chinese drug developers.
- Royalty Pharma opens Asia-Pacific office in Hong Kong to target China biotech royalties.
- Chinese biotech out-licensing deal value surged 87% year-over-year through May 2026.
- US regulatory tightening on biotech investments adds uncertainty but deal momentum continues.
What happened
Royalty Pharma, founded in 1996 and headquartered in New York, recently opened its first Asia-Pacific office at the IFC in Hong Kong. This move reflects growing interest in the Chinese biotech market, which has seen a 30% year-over-year rise in business development deals and an 87% jump in corresponding deal values through the end of May 2026. The company specializes in providing upfront capital to drug developers in exchange for future royalty payments, offering an alternative funding model that reduces reliance on traditional venture capital or public markets.
Chinese biotechnology firms have increasingly engaged in out-licensing and co-development arrangements with Western pharmaceutical companies. Notable recent deals include CStone Pharmaceuticals granting commercialization rights in Australia and New Zealand to Arrotex Pharmaceuticals for a cancer immunotherapy drug and a research collaboration between Shanghai’s Abbisko Therapeutics and US giant Eli Lilly valued up to $1.9 billion in combined payments and royalties.
Why it matters
The shift toward royalty financing is critically important as Chinese biotech companies navigate a challenging external investment environment. US lawmakers have introduced legislation, specifically the Biotech Investment National Security Act (Binsa), aimed at tightening scrutiny of outbound investments in the pharmaceutical and biotechnology sectors. Despite this, experts forecast the total out-licensing deal value between Chinese firms and Western partners to nearly double to around $240 billion in 2026 from $136 billion in 2025.
Hong Kong’s status as a financial and biotechnology hub provides a strategic advantage for Royalty Pharma and other multinational firms seeking to engage in Asia-Pacific cross-border pharmaceutical deals. This development signals increasing international confidence in Chinese biotech innovation, which spans a broad array of advanced technologies including nucleic acids, radiopharmaceuticals, antibody-drug conjugates, and cellular therapies.
What to watch next
Market participants should monitor the enactment and implementation details of Binsa and other regulatory actions, as these could impact the speed and scale of cross-border biotech collaborations and financing arrangements. Meanwhile, the growing trend toward asset-by-asset deal structures and co-development partnerships rather than outright buyouts is expected to continue in the near term, reflecting the reasonably priced and high-quality nature of Chinese biotech pipelines.
Additionally, the expansion of Royalty Pharma and other investors in the Asia-Pacific region may accelerate innovation funding opportunities for late-stage biotech startups. Industry observers also anticipate that by 2040, approximately 35% of new drugs approved by the US FDA will originate from Chinese companies, up sharply from just 5% today, underscoring the strategic importance of this sector’s evolving funding landscape.